Clinical Drug Investigation

, Volume 14, Issue 5, pp 392–399 | Cite as

Maintenance Treatment with Interferon in Multiple Myeloma

A Survival Meta-Analysis
  • Sabrina Trippoli
  • Paola Becagli
  • Andrea Messori
  • Enrico Tendi
Outcomes Research


Some clinical trials have shown that long-term treatment with alpha interferon (IFN) in patients with multiple myeloma can improve survival in comparison with patients not given IFN, but other studies have found no survival benefit in patients treated with IFN. We utilised the clinical material reported in these trials to conduct a meta-analysis on long-term survival. The survival curves published in each of these studies were analysed to determine the mean lifetime survival (MLS) for treated patients and controls using Gompertz’ extrapolation to infinity of the survival curves. Values of MLS were then pooled using standard meta-analytic techniques. Our meta-analysis showed that maintenance treatment with IFN did not improve MLS at levels of statistical significance. The MLS was 3.9 years per patient in the IFN group versus 3.4 years per patient in the controls (p = 0.095). Because the level of statistical significance was borderline, a lifetime cost-effectiveness analysis was undertaken to determine the cost per life-year gained using IFN. This cost was found to be around $US84 000 per life-year gained, a value suggesting an unfavourable pharmacoeconomic profile. We conclude that the survival advantage of maintenance treatment with IFN in myeloma patients, if any, has a small clinical relevance and demonstrates an intermediate or unfavourable pharmacoeconomic ranking.


Multiple Myeloma Root Mean Square Error Adis International Limited Drug Invest Myeloma Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Browman GP, Bergsagel D, Sicheri D, et al. Randomised trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada clinical trials group. J Clin Oncol 1995; 13: 2354–60PubMedGoogle Scholar
  2. 2.
    Mandelli F, Avvisati G, Amadori S, et al. Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. N Engl J Med 1990; 322: 1430–4PubMedCrossRefGoogle Scholar
  3. 3.
    Ludwig H, Cohen AM, Polliack A, et al. Interferon-alpha foe induction and maintenance in multiple myeloma: results of two multicenter randomised trials and summary of other studies. Ann Oncol 1995; 6: 467–76PubMedGoogle Scholar
  4. 4.
    Powles R, Raje N, Cunningham D, et al. Maintenance therapy for remission in myeloma with Intron A following high-dose melphalan and either an autologous bone marrow transplantation or peripheral stem cell rescue. Stem Cells 1995: 13 Suppl. 2: 114–7PubMedGoogle Scholar
  5. 5.
    Salmon ES, Crowley JJ, Grogon TM, et al. Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study. J Clin Oncol 1994; 11: 2405–14Google Scholar
  6. 6.
    Peest D, Deicher H, Leo R, et al. A comparison of polychemotherapy and melphalan/prednisone for primary remission induction, and interferon alpha for maintenance treatment, in multiple myeloma. A prospective trial of the German myeloma treatment group. Eur J Cancer 1995; 31: 146–51CrossRefGoogle Scholar
  7. 7.
    Westin J, Rodjer S, Cortelezzi A, et al. Interferon alpha-2b versus no maintenance therapy during the plateau phase in multiple myeloma: a randomised study. Br J Haematol 1995; 89: 561–8PubMedCrossRefGoogle Scholar
  8. 8.
    Mark DB, Hlatky MA, Califf RM, et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995; 332: 1418–24PubMedCrossRefGoogle Scholar
  9. 9.
    Messori A, Becagli P, Trippoli S, et al. Cost-effectiveness of adjuvant chemotherapy with cyclophosphamide + methotrexate +fluorouracil in patients with node-positive breast cancer. Eur J Clin Pharmacol 1996; 51: 111–6PubMedCrossRefGoogle Scholar
  10. 10.
    Messori A, Bonistalli L, Costantini M, et al. Cost-effectiveness of adjuvant intraportal chemotherapy in colorectal cancer. J Clin Gastroenterol 1996; 23: 269–74PubMedCrossRefGoogle Scholar
  11. 11.
    Messori A, Trippoli S, Becagli P, et al. Pharmacoeconomic profile of paclitaxel as first-line treatment for patients with advanced ovarian cancer: a lifetime cost-effectiveness analysis. Cancer 1996; 78: 2366–73PubMedCrossRefGoogle Scholar
  12. 12.
    Messori A, Becagli P, Trippoli S, et al. A retrospective cost-effectiveness analysis of interferon as adjuvant therapy in high-risk resected cutaneous melanoma. Eur J Cancer 1997; 33: 1373–9PubMedCrossRefGoogle Scholar
  13. 13.
    Messori A, Bonistalli L, Costantini M, et al. Cost-effectiveness of autologous bone marrow transplantation in patients with relapsed non-Hodgkin’s lymphoma. Bone Marrow Transplant 1997; 19: 275–81PubMedCrossRefGoogle Scholar
  14. 14.
    Varoli G. Matematica Finanziaria. Patron, Bologna, 1990: 72–5Google Scholar
  15. 15.
    Lee ET. Statistical methods for survival data analysis. Belmont, CA: Lifetime Learning, 1980: 50–3Google Scholar
  16. 16.
    Messori A. Survival curve fitting using the Gompertz function: a methodology for conducting cost-effectiveness analyses on mortality data. Comput Meth Progr Biomed 1997; 52: 157–64CrossRefGoogle Scholar
  17. 17.
    Simes RJ. Confronting publication bias: a cohort design for meta-analysis. Stat Med 1987; 6: 11–29PubMedCrossRefGoogle Scholar
  18. 18.
    Thompson SG. Why sources of heterogeneity in meta-analysis should be investigated. BMJ 1994; 309: 1351–5PubMedCrossRefGoogle Scholar
  19. 19.
    L’Abbè KA, Detsky AS, O’Rourke K, et al. Meta-analysis in clinical research. Ann Intern Med 1987; 107: 224–33PubMedGoogle Scholar
  20. 20.
    Hjorth M and the Nordic Myeloma Study Group. Interferon alfa-2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma. Ann Intern Med 1996; 124: 212–22Google Scholar
  21. 21.
    Ludwig H, Cohen AM, Huber H, et al. Interferon alfa-2b with VMCP compared to VMCP alone for induction and interferon alfa-2b compared to controls for remission maintenance in multiple myeloma: interim results. Eur J Cancer 1991; 27: S40–S45PubMedGoogle Scholar
  22. 22.
    Gertz MA, Kalish LA, Kyle RA, et al. Phase 111 comparing vincristine, doxorubicine and dexamethasone (VAD) chemotherapy with VAD plus recombinant interferon alfa-2b in refractory or relapsed multiple myeloma. Am J Clin Oncol 1995; 18: 475–80PubMedCrossRefGoogle Scholar
  23. 23.
    Cooper MR, Dear K, McIntyre OR, et al. A randomised clinical trial comparing melphalan/prednisone with or without interferon alfa-2b in newly diagnosed patients with multiple myeloma: a Cancer and Leukaemia Group B study. J Clin Oncol 1993; 11: 155–60PubMedGoogle Scholar
  24. 24.
    McSweeney EN, Tobias JS, Blackman G, et al. Double hemi-body irradiation (DHBI) in the management of relapsed and primary chemoresistant multiple myeloma. Clin Oncol 1993; 5: 378–83CrossRefGoogle Scholar
  25. 25.
    Giles FJ, McSweeney EN, Richards JD, et al. Prospective randomised study of hemy-body irradiation with and without subsequent maintenance recombinant alpha 2b interferon on survival in patients with relapsed multiple myeloma. Eur J Cancer 1992; 28A: 1392–5PubMedCrossRefGoogle Scholar
  26. 26.
    Schofield JR, Robinson WA, Murphy JR. Low doses of interferon-alfa are as effective as higher doses in inducing remissions and prolonging survival of chronic myeloid leukemia. Ann Intern Med 1994; 121: 736–44PubMedGoogle Scholar
  27. 27.
    Bataille R, Harousseau JL. Multiple myeloma. N Engl J Med 1997; 336: 1657–64PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1997

Authors and Affiliations

  • Sabrina Trippoli
    • 1
  • Paola Becagli
    • 1
  • Andrea Messori
    • 1
  • Enrico Tendi
    • 1
  1. 1.Drug Information Centre, Pharmaceutical Service, Policlinico Careggi HospitalAzienda Ospedaliera CareggiFlorenceItaly

Personalised recommendations